Via Minneapolis Star Tribune
“Minnesota’s remdesivir study is one of three randomized controlled clinical trials announced by the U’s Medical School on Friday that will use existing drugs to try to treat people who have been exposed to COVID-19… In addition to the Ebola drug, the U studies will examine the effects of drugs to treat high blood pressure and malaria to see if they can prevent or slow down infections of COVID-19. “
“Medical School Dean Dr. Jakub Tolar said the university has been designated by federal officials as the regional treatment center for states including Wisconsin, Michigan and Illinois. ‘I think that with the proper safety measures, like hand-washing, limiting travel, and limiting the large gatherings, we will be able to flatten the curve. But that is most likely going to take months,’ Tolar said. ‘But we don’t know if it’s going to go away. It’s an unknown infection. That is the whole point.'”
Read the rest of “University of Minnesota to test three drugs for COVID-19 patients”
MAA COVID-19 INFORMATION DISCLAIMER:
The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service. The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.
The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via this email or other communications.
